GBI Research
GBI Research Market Research Reports
| Title | published | price | |
|---|---|---|---|
Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive GrowthBy GBI Research
Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth Summary The women's health therapy area covers medical disorders tha ... |
01-Jan-2019 | $4995 | |
Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent ExpiryBy GBI Research
Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry Summary The rheumatic disorder therapy area is multi-disciplinary in ... |
01-Jan-2019 | $4995 | |
Gastrointestinal Diseases Drug Development Pipeline Review, 2018By GBI Research
Summary This report provides an overview of the pipeline landscape for gastrointestinal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic developm ... |
20-Dec-2018 | $3995 | |
Renal Diseases Drug Development Pipeline Review, 2018By GBI Research
Summary This report provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chr ... |
19-Dec-2018 | $3995 | |
Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel TherapiesBy GBI Research
Summary Atopic dermatitis (AD), also called atopic eczema, is a chronic, pruritic, inflammatory skin disease arising from a complex interrelationship of environmental, immunologic, genetic, and pharmacologic factors, with ... |
15-Dec-2018 | $4995 | |
Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the MarketBy GBI Research
Summary Non-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver disease (NAFLD), characterized by a buildup of fat in the liver. Globally, the NAFLD prevalence rate is estimated to be around 25 ... |
03-Dec-2018 | $4995 | |
Chronic Respiratory Disease Drug Development Pipeline Review, 2018By GBI Research
Summary This report provides an overview of the pipeline landscape for chronic respiratory diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic devel ... |
30-Nov-2018 | $3995 | |
Transplant Complications Drug Development Pipeline Review, 2018By GBI Research
Summary This report provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic developme ... |
30-Nov-2018 | $3995 | |
Epilepsy Therapeutics in Asia-Pacific Markets to 2024 - Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market GrowthBy GBI Research
Summary Epilepsy is a chronic disorder of the brain with substantial morbidity. There are more than 65 million people with epilepsy globally, and this is growing because of the rapidly increasing population. The rising pre ... |
01-Nov-2018 | $4995 | |
Optic Nerve Disorders Drug Development Pipeline Review, 2018By GBI Research
Optic Nerve Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information f ... |
26-Oct-2018 | $3995 | |
Hereditary Hematological Disorders Drug Development Pipeline Review, 2018By GBI Research
Hereditary Hematological Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for hereditary hematological disorders. It provides comprehensive information on th ... |
25-Oct-2018 | $3995 | |
Frontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis BullosaBy GBI Research
Orphan and rare dermatological diseases are considerably diverse in terms of pathophysiology, clinical presentation and disease severity. Many of these conditions are extremely debilitating and can even be life-threatening in some cases. D ... |
11-Oct-2018 | $6995 | |
Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018By GBI Research
This report provides an overview of the pipeline landscape for dermatological burns, scars and ulcers. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pressure ulc ... |
28-Sep-2018 | $3995 | |
Pain Drug Development Pipeline Review, 2018By GBI Research
This report provides an overview of the pipeline landscape for pain disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-operative pain, fibromyalgia, c ... |
24-Sep-2018 | $3995 | |
Depression and Anxiety Disorders Drug Development Pipeline Review, 2018By GBI Research
Depression and Anxiety Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for depression and anxiety disorders. It provides comprehensive information on th ... |
21-Sep-2018 | $3995 | |
Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market GrowthBy GBI Research
Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth Summary Dermatology is a highly diverse ... |
01-Sep-2018 | $4995 | |
Heart Failure Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Rising Geriatric Population and Increasing Uptake of Recently Launched TherapyBy GBI Research
Heart Failure Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Rising Geriatric Population and Increasing Uptake of Recently Launched Therapy Summary Heart failure (HF) is a life-threatening syndrome with ... |
01-Sep-2018 | $4995 | |
Blood Pressure Disorders Drug Development Pipeline Review, 2018By GBI Research
Blood Pressure Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under ... |
31-Aug-2018 | $3995 | |
Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018By GBI Research
Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for pancreatic and bile duct cancer. It provides comprehensive information on the ther ... |
31-Aug-2018 | $3995 | |
Osteoporosis Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by ongoing Transition from Anti-resorptive Agents to Anabolic Therapies, Rising Prevalence, and Growing AwarenessBy GBI Research
Summary Osteoporosis is a “silent epidemic” and as per the WHO declarations, it is a priority health issue. Osteoporosis is a disruption of bone architecture and decrease in bone mass, leading to a number of co ... |
01-Aug-2018 | $4995 | |
- + 1 888 391 5441
- [email protected]
